Sun Pharmaceutical Industries, India's largest drugmaker, is preparing to raise 100 billion rupees (about $1.2 billion) through a bond sale, according to reports citing merchant bankers. The company is marketing two tranches of bonds with maturities of just over five years, offering coupons in the range of 8.05% to 8.20%. Bids are due on Thursday.
The sale is notable not just for its size but for the structure of one tranche. A portion of the offering, up to 30 billion rupees, is "puttable," meaning investors can demand their money back after 17 months, even though the bonds legally mature in just over five years. The other tranche, at least 50 billion rupees with a 20 billion rupee greenshoe option, is a plain-vanilla "bullet" bond that repays the principal at maturity.
What is a puttable bond?
For everyday investors, a puttable bond is a type of debt security that gives the holder the right to sell the bond back to the issuer at a predetermined date before maturity. In this case, investors in the puttable tranche can exit after 17 months, which provides an early exit route if interest rates rise or if they need liquidity. This feature typically makes the bond more attractive to investors, but it also means the issuer faces the risk of having to repay early.
The greenshoe option on the larger tranche allows the underwriters to sell additional bonds if demand is strong, potentially increasing the total size of the offering beyond the initial 100 billion rupees.
Why is Sun Pharma raising funds?
Sun Pharma, a global pharmaceutical giant with a market value of over $40 billion, is known for its portfolio of branded generics and specialty drugs. Companies often issue bonds to refinance existing debt, fund capital expenditure, or for general corporate purposes. While the specific use of the proceeds has not been disclosed, such large-scale bond sales are common among Indian corporates looking to lock in long-term funding at fixed rates.
The timing is also significant. Indian bond markets have been active as companies take advantage of relatively stable interest rates. However, the backdrop includes a weakening rupee, which has been hovering near record lows against the dollar, and rising global oil prices. These factors can influence borrowing costs and investor appetite.
What it means for investors
For bond investors, the sale offers a chance to earn a yield of around 8% to 8.2% over a five-year horizon, which is attractive compared to bank fixed deposits that typically offer lower rates. The puttable feature adds flexibility, but it also means that if interest rates fall, the company might be inclined to call the bonds or investors might choose to hold longer. Conversely, if rates rise, investors can exit early and reinvest at higher yields.
For equity investors, a large bond sale is not necessarily a negative. It can signal that the company is confident in its cash flows and is locking in funding at reasonable rates. However, it also adds to the company's debt load, which could increase interest expenses. Investors should watch how the funds are deployed and whether they lead to higher returns.
The bond sale comes at a time when Indian markets are seeing increased activity in corporate debt. Other companies, such as Rakuten's recent bond issuance, highlight the global trend of companies tapping debt markets for refinancing and liquidity. In India, the rupee's weakness has been a concern, with the central bank stepping in to stabilize the currency, as seen in recent interventions.
Risks to consider
Investors should be aware of the risks. If interest rates rise, the value of existing bonds falls, though the puttable feature mitigates this. Also, credit risk is a factor, but Sun Pharma is a highly rated issuer, so default risk is low. The rupee's depreciation could also affect foreign investors, who might see returns eroded when converting back to their home currency.
Overall, this bond sale is a significant event in India's corporate debt market. It offers a relatively safe way to earn a decent yield, with a twist that gives investors some control. For those watching the broader market, it's a sign that large Indian companies are confident enough to raise long-term capital, even amid currency and oil price headwinds.
As always, investors should consider their own financial goals and risk tolerance before participating in any bond offering.
